New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

-

 


A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs. The findings were published in the December issue of The Journal of Nuclear Medicine.

Beta-emitting radioactive iodine is the standard treatment for patients with recurrent or metastatic differentiated thyroid cancer (DTC) after total thyroidectomy. However, despite repeated administration, some patients experience disease progression and are classified as refractory to radioactive iodine. At that point, molecular-targeted agents, such as kinase inhibitors, are used to treat radioactive iodine-resistant DTC.

To address this issue, Watabe and colleagues developed a targeted alpha-therapy using the radionuclide 211At-NaAt. In a phase I clinical trial, they utilized a dose escalation model (1.25, 2.5, and 3.5 MBq/kg) to assess the adverse events, pharmacokinetics, absorbed dose, and therapeutic efficacy of a single intravenous dose of 211At-NaAt in patients with radioactive iodine-refractory DTC. Response was evaluated by thyroglobulin measurement, CT imaging, and 131I SPECT imaging.

The researchers found that targeted alpha-therapy using 211At-NaAt can be safely administered to patients with DTC. Although dose-limiting toxicities were observed with the 3.5 MBq/kg dose, toxicities remained within a tolerable range. Preliminary evidence of efficacy was observed in some patients treated with either 2.5 or 3.5 MBq/kg, including thyroglobulin reductions of greater than 50 percent and decreased uptake in radioactive iodine-avid lesions on 131I SPECT.

"Our findings provide the first evidence that 211At based therapy is both feasible and therapeutically promising in patients who no longer respond to conventional radioactive iodine," stated Watabe. "Because 211At (astatine) therapy may achieve disease control without requiring molecular targeted drugs, it has the potential to reduce treatment burden, limit adverse effects associated with systemic therapies, and broaden access to effective care for patients with refractory disease."

"In addition," he noted, "211At can be produced using accelerator cyclotrons, and its availability will expand globally as more production facilities come online. The successful clinical application of 211At in this study marks an important milestone for the field, opening the door to widespread adoption of cyclotron-based alpha-therapy and accelerating future innovations in molecular imaging and targeted radionuclide therapy."

#ResearchChemistry, #ChemicalInnovation, #Science, #ScienceResearch, #ScientificResearch, #ResearchAndDevelopment, #ChemistryEducation, #ChemistryExperiments, #ChemistryLab, #ChemistryStudents, #ChemistryStudy, #OrganicChemistry, #InorganicChemistry, #PhysicalChemistry, #AnalyticalChemistry, #Biochemistry, #MaterialsChemistry, #TheoreticalChemistry, #AppliedChemistry, #MedicinalChemistry

Comments

Post a Comment

Popular posts from this blog

Avoiding prostate cancer screening increases risk of death

-
Image
  Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group. An analysis of data from across seven countries from the world's largest prostate cancer screening study, the European Randomized study of Screening for Prostate Cancer (ERSPC), is presented this weekend at the European Association of Urology (EAU) Congress in Madrid. Prostate cancer is the most common form of cancer in men in 112 countries, with prevalence expected to double by 2040. If introduced on a national scale, prostate cancer screening programmes that measure levels of prostate-specific antigen (PSA) in the blood have the potential to give men earlier access to treatment, a better chance of being cured. They can also prevent costly treatment associated with advanced prostate cancer. Long-term follow-up data from the ERSPC consistently report that PSA screening programmes can lead to a 20% re...
Read more

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

-
Image
  Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the "EchoBack CAR T-cell," which could soon be a game changer in the field of cancer immunotherapy . The work, published in the scientific journal Cell, is a groundbreaking new approach that could overcome major obstacles in treating tumors that are not usually candidates for immunotherapy, while keeping healthy tissue safe. Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized therapy in which cancer-fighting T-cells are drawn directly from the blood of a patient and given genetic modifications to enhance their ability to target and kill cancerous cells. The USC Alfred E. Mann Department ...
Read more

The Role of Analytical Chemistry in Industry and Manufacturing

-
Image
Industry and the manufacturing sector use multiple analytical chemical methods, whether for new product development, processing, or quality control. This article outlines the research to be presented at Pittcon on the advances being made in analytical chemistry and their application in industry and manufacturing. Spectroscopy is a valuable analytical tool for a wide range of sectors. Several talks will focus on Raman spectroscopy as a highly versatile analytical tool, which can be used in chemical processing from laboratory to manufacturing. Raman spectroscopy’s use in polymer science to measure and control chemical processes is a particular focus. The technique is becoming increasingly relevant as chemical manufacturing expands to include new developments such as batch reactions, microreactors, flow synthesis, and continuous processes. Pittcon will hear examples of using Raman spectroscopy to improve process efficiency and predict reaction end-times and physical properties of chemical...
Read more